Shijiazhuang Yiling Pharmaceutical Co: 2024 net loss driven by sales drop, inventory write-downs, and high R&D; cost control prioritized

About this update from Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A

2024 saw a sharp revenue decline and a net loss due to lower respiratory product sales, inventory write-downs, and high R&D costs. Cardiovascular products remained the main revenue driver, while overseas sales grew modestly. The company will focus on cost control and innovation in 2025.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A